What Can We Help You Find?

Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.

02/5
2020

Faulty Immune System May Lead to Lung Cancer

From WebMD An immune system that's not functioning normally may lead to lung cancer in patients who don't smoke, a new study suggests. "A strong immune system helps to keep inflammation under control and chronic inflammation …

02/4
2020

Is Lung Cancer Related to Air Pollution?

From Dana Farber Cancer Center Pollution in the air was responsible for 223,000 lung cancer deaths worldwide in 2010, research shows.The findings prompted the World Health Organization to classify air pollution, for the first time, as a…

02/4
2020

Acquired Drug Resistance Strategy

From Dana Farber Cancer Institute Acquired Drug Resistance: Dana-Farber’s Pasi Jänne, MD, PhD, and his colleagues say they have discovered a mechanism within lung cancer cells that enables the cells to lie dormant and avoid destruct…

01/8
2020

Death Rate Drop: Lung Cancer Research Key

From Los Angeles Times Researchers on Wednesday (January 8, 2020) reported the largest-ever one-year decline in the U.S. cancer death rate, a drop they credited to advances in lung-tumor treatments. The overall cancer death rate has …

01/7
2020

Small Cell Lung Cancer (SCLC)

From OncLive Sea Sponge Product and Small Cell Lung Cancer (SCLC) Charles Rudin, MD, PhD The treatment of relapsed and refractory small cell lung cancer (SCLC) is really an area of very active investigation right now. There are a …

12/4
2019

Treatment Refusal for Small Cell Lung Cancer

Treatment refusal for small cell lung cancer studied: Small-cell lung cancer (SCLC) accounts for about 15% of all lung cancers, and the disease is not associated with a great outcome rate, with a 5-year survival of only around 6%. But S…

12/4
2019

How Are We Failing Lung Cancer Patients so Miserably?

From Medscape Oncology Failing Lung Cancer Patients The medical community is failing lung cancer patients. We are doing an unconscionably poor job of delivering appropriate targeted therapies to our patients. That's the only conclusi…

11/19
2019

Liquid Biopsies and NSCLC

From LungCancerNews.org Liquid Biopsies and NSCLC Genomic analysis of plasma cell free DNA (cfDNA) using liquid biopsies has been adopted widely in academic cancer centers. (It has not necessarily been adopted as widely in community…

10/25
2019

Inadequate Lung Cancer Screening Guidelines for First Responders

From EurekAlert Lung Cancer Screening Guidelines for First Responders National lung cancer screening guidelines are inadequate to diagnose patients who contract lung cancer from occupational exposure, including first responders, acco…

10/25
2019

Liquid Biopsies and Molecular Testing in Lung Cancer

From Oncology Learning Network At the 2019 Perspectives in Thoracic Oncology meeting, Marc Ladanyi, MD, Chief of Molecular Diagnostics at Memorial Sloan Kettering Cancer Center (MSKCC), New York, spoke with Oncology Learning Network …

Research is imperative to improve treatment and management of all diseases and that’s particularly true of lung cancer. It’s creation of new knowledge, it’s discovery. It’s how we learn how to improve management of symptoms, to improve survival. ~Dr. David Johnson